Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y

S Lin1, D Boey, M Couzens

  • 1Neurobiology Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia.

Neuropeptides
|January 4, 2005
PubMed

Insights

Gene knockout studies reveal compensatory changes in Y receptor expression. Deleting one Y receptor impacts others, altering binding site levels and patterns in mouse models.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Gene knockout models are crucial for understanding Y receptor function.
  • Discrepancies exist between knockout studies and pharmacological interventions.
  • Germ-line deletion of one Y receptor may affect the expression of others.

Purpose of the Study:

  • To investigate compensatory changes in Y receptor mRNA and protein expression in knockout models.
  • To analyze alterations in radio-ligand binding sites following gene deletion.
  • To explore the functional consequences of Y receptor gene deletion.

Main Methods:

  • Generation of Y receptor single, double, and triple knockout mice.
  • Radio-ligand binding assays using [(125)I]-PYY.
  • Competition binding experiments with Y receptor-specific ligands.
  • Analysis of mRNA expression levels.

Main Results:

  • Significant up- and down-regulation of Y receptor binding sites observed in knockout models.
  • Hippocampal Y receptors strongly down-regulated in Y(1) knockout mice.
  • Y(2) knockout mice showed altered expression patterns with up-regulation in the dentate gyrus.
  • Y(5) receptor mRNA increased in triple knockouts; unidentified Y receptors suggested by binding data.

Conclusions:

  • Germ-line gene deletion of Y receptors induces compensatory changes in expression and function.
  • These compensatory mechanisms explain discrepancies between knockout and pharmacological studies.
  • Evidence suggests the existence of novel Y receptors beyond the known subtypes.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...